"We Envision Growth Strategies Most Suited
to Your Business"

Spinal Cord Stimulation Market to Reach $4.12 Billion by 2027; Acquisition of St. Jude Medical by Abbott to Bolster Growth

January 13, 2021 | Healthcare

The global spinal cord stimulation market size is expected to reach USD 4.12 billion by 2027. The growing awareness about the side effects of opioids will simultaneously spur demand for non-opioid therapies, which, in turn, will foster the healthy growth of the market, mentioned in a report, titled Spinal Cord Stimulation Market Size, Share & COVID-19 Impact Analysis, By Product (Rechargeable and Non-rechargeable), By Disease Indication (Failed Back Surgery Syndrome (FBSS), Degenerative Disc Disease (DDD), Complex Regional Pain Syndrome (CRPS), Arachnoiditis, and Others) By End User (Hospitals, Ambulatory Surgery Centers, and Specialty Clinics), and Regional Forecast, 2020-2027.” The market size stood at USD 2.88 billion in 2019 and is expected to exhibit a CAGR of 8.0% between 2020 to 2027.

CE Mark Approval of Senza® Omnia™ Spinal Cord Stimulation System to Aid Development

Nevro Corp, a global medical device company focused on evidence-based solutions for the treatment of chronic pain, announced that it has received CE mark approval for the Senza® Omnia™ Spinal Cord Stimulation (SCS) system. The innovative solution will be used for the treatment of chronic pain. The Omnia system is a new SCS platform that consists of several new components; the new Omnia programmer is the first, which will allow physicians to deliver the widest array of waveforms across the full SCS frequency spectrum, either separately or paired together with HF10. The second element of the system will support grander programming capacity, allowing the flexibility to inflate the HF10 algorithm, thus offering physicians the power to provide additional waveforms through the remote. Moreover, the third component includes a slimmer patient charger with an enhanced user interface. The system has an updated and upgradeable implantable pulse generator, which can be changed whenever required. The approval of the Senza® Omnia™ Spinal Cord Stimulation (SCS) system will have an excellent effect on the global market.

To get a detailed report summary and research scope of this market, click here:


Rising Advancements in Stimulator System to Incite Market Expansion

The increasing investments in R&D activities to introduce compact spinal cord stimulators will boost the healthy growth of the market. For instance, the Freedom SCS system launched by Stimwave LLC is around 5% of the size of the current Implantable Pulse Generators (IPG) available in the market. Stimgenics, a U.S.-based company announced that it has developed a novel spinal cord stimulation waveform called Differential Target Multiplexed (DTM) SCS. The company was acquired by Medtronic in January 2020. Besides, the increasing innovation and advancement in impulse generation are expected to drive the market.

Strong Portfolio of Medtronic to Support Industry

The market is dominated by major companies; predominately by Medtronic owing to its strong portfolio. The growing focus on R&D and acquisitions will help the company in developing innovative devices to manage chronic pain. Spinal cord stimulators offered by the company have long battery life, easy to use with better clinical outcomes, and good customer support services, and hence are having a high preference among healthcare providers.  Similarly, Boston Scientific and Abbott are in close competition. In January 2017, Abbott completed the acquisition of St. Jude Medical, Inc. Nonetheless, the emergence of new companies such as Nevro Corp, with its proprietary HF10 therapy has observed remarkable demand, which, in turn, will intensify competition among companies.

The Report Lists the Key Companies in the Spinal Cord Stimulation Market:

  • Boston Scientific Corporation (Massachusetts, U.S.)

  • Medtronic (Dublin, Ireland)

  • Abbott (Illinois, U.S.)

  • Nevro Corp (California, U.S.)

  • Nuvectra (Texas, U.S.)

  • Stimwave LLC (Florida, U.S.)

  • Other prominent players

Further Report Findings:

Regional Analysis: North America is expected to hold the largest share due to the rapid adoption of neuromodulation therapies in the region. The increasing prevalence of chronic pain and favorable health reimbursement will boost the market in the region.

Leading Segment: The non-rechargeable segment is expected to account for the maximum share owing to the rising prevalence of chronic back pain coupled with an increasing number of failed back surgeries.

The Spinal Cord Stimulation Market is Segmented into:



Study Period


Base Year


Forecast Period


Historical Period



Value (USD Billion)





By Product

  • Rechargeable

  • Non-rechargeable

By Disease Indication

  • Failed Back Surgery Syndrome (FBSS)

  • Degenerative Disc Disease (DDD)

  • Complex Regional Pain Syndrome (CRPS)

  • Arachnoiditis

  • Others

By End User

  • Hospitals

  • Ambulatory Surgical Centers

  • Specialty Clinics

By Geography

  • North America

    • By Product

    • By Disease Indication

    • By End User

    • By Country

  • Europe

    • By Product

    • By Disease Indication

    • By End User

    • By Country/Sub-region

  • Asia Pacific

    • By Product

    • By Disease Indication

    • By End User

    • By Country/Sub-region

  • Rest of World

    • By Product

    • By Disease Indication

    • By End User

Spinal Cord Stimulation Market
  • PDF
  • 2019
  • 2016-2018
  • 150


  • 4850

Our Clients

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.